Sign in

    Viatris Inc (VTRS)

    You might also like

    Viatris is a global healthcare company that operates through a diversified portfolio of branded and generic products across various markets. The company is organized into four main business segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets, with the Developed Markets segment being the largest contributor to its revenue . Viatris offers a wide range of pharmaceuticals, including well-known branded products like Lipitor®, Norvasc®, Lyrica®, and EpiPen® Auto-Injectors, as well as a stable generics segment featuring complex generics such as Wixela and Breyna . The company emphasizes new product launches and continues to invest in its pipeline, particularly in complex injectables and eye care products, to drive future growth .

    1. Branded Pharmaceuticals - Offers a range of well-known branded medications, including Lipitor®, Norvasc®, Lyrica®, and EpiPen® Auto-Injectors, making up a significant portion of the company's portfolio.
    2. Generic Pharmaceuticals - Provides a stable selection of generic drugs, including complex generics like Wixela and Breyna, contributing significantly to the company's revenue.
    3. Developed Markets - Focuses on operations in North America and Europe, contributing the largest share to the company's overall revenue.
    4. New Product Launches - Drives growth through recent product introductions, such as Breyna™ in the U.S., and continues to expand its offerings.
    5. Pipeline Investments - Invests in future growth through the development of complex injectables and eye care products.
    NamePositionStart DateShort Bio
    Scott A. SmithChief Executive OfficerApril 1, 2023Scott A. Smith has served as the CEO of Viatris Inc. since April 1, 2023. He was previously the President of BioAtla, Inc. and held various executive roles at Celgene Corporation .
    Theodora (Doretta) MistrasChief Financial OfficerMarch 1, 2024Theodora Mistras has served as the CFO of Viatris since March 1, 2024. She joined as CFO-elect on January 1, 2024, and was previously Managing Director of Healthcare Investment Banking at Citigroup Global Markets .
    Paul CampbellChief Accounting Officer and Corporate ControllerNovember 16, 2020Paul Campbell has served as Viatris' Chief Accounting Officer and Corporate Controller since November 16, 2020. He was previously Mylan's Chief Accounting Officer, Senior Vice President, and Controller .
    Brian RomanChief Legal OfficerApril 1, 2024Brian Roman has served as Viatris' Global General Counsel since November 16, 2020, and was named Chief Legal Officer on April 1, 2024. He oversees the company's global legal organization .
    Dr. Corinne Le GoffChief Commercial OfficerApril 15, 2024Dr. Corinne Le Goff has served as the Chief Commercial Officer of Viatris Inc. since April 15, 2024. She previously held roles at Imunon, Inc., Moderna, Inc., and Amgen Inc. .
    1. You've mentioned confidence in delivering $450 million to $550 million in new product revenue next year, including key products like glucagon, iron sucrose, and liraglutide; can you provide specific guidance on the expected contributions from each of these products and any potential risks that could impact these projections?
    2. With supply chain delays affecting your ARV products in emerging markets, when do you expect to fully resolve these issues, and what measures are you implementing to prevent similar disruptions in the future?
    3. Given your leverage target is nearly achieved and the stock is trading at a low multiple, how do you plan to balance capital allocation between share repurchases and business development investments, and what factors will influence a more aggressive approach towards buybacks versus investing in pipeline assets?
    4. Regarding your recent licensing agreement for sotagliflozin, which is expected to start contributing to revenue around 2027, can you clarify how this aligns with your strategy for near-term growth and what interim milestones investors should watch for?
    5. With potential generic competition for Symbicort expected next year from competitors like Teva, how do you plan to address the anticipated market share erosion, and what strategies are in place to mitigate the impact on your revenues?
    Program DetailsProgram 1Program 2
    Approval DateFebruary 28, 2022 February 26, 2024
    End Date/DurationNo expiration No expiration
    Total Additional Amount$1.0 billion $1.0 billion
    Remaining Authorization$0.5 billion $1.0 billion
    DetailsPart of strategy to enhance shareholder value Increase return of capital to shareholders
    CustomerRelationshipSegmentDetails
    McKesson Corporation
    Wholesale distribution partner
    All
    Represents 10% of consolidated net sales in 2023.No individual AR data available.
    AmerisourceBergen Corporation
    Wholesale distribution partner
    All
    Represents 10% of consolidated net sales in 2023.No individual AR data available.
    Cardinal Health, Inc.
    Wholesale distribution partner
    All
    Represents 5% of consolidated net sales in 2023.No individual AR data available.
    NameStart DateEnd DateReason for Change
    Deloitte & Touche LLP1976 PresentCurrent auditor.
    KPMG LLPN/ANovember 19, 2020 The change was made in connection with the Combination of Mylan and Pfizer's off-patent branded and generic established medicines business. Mylan, the accounting acquirer in the Combination, had Deloitte & Touche LLP as its independent registered public accounting firm since 1976.